The FDA on April 11, 2025, approved OPDIVO® with YERVOY® for the first-line treatment of adult patients with unresectable or metastatic HepatoCellular Carcinoma (HCC). OPDIVO® and YERVOY® are products of Bristol Myers Squibb Company.
Bottom Ad
Advertisement
Subscribe
